----------------------------------------------
------------------------------------------------------------------
When you're talking about the more prevalent type of tumor in the brain, glioblastoma research is definitely something worth talking about. The potential that this method can possess is one of the greatest that I have seen. There is a high level of work done on the matter, which is tough to argue against. With so many stories posted about the matter, I would like to think that I have placed all of my attention on those which are the most deserving, of which there are many.
An article that was posted on Seeking Alpha talked about a 60-patient phase I/II trial about to be done. Northwest Biotherapeutics would be in charge as the process would be conducted at the MD Anderson Cancer Center. With the immunotherapy DCVax-Direct put into effect, it would grant patients a standard dose. This would then work into the Phase II portion of the experiment, which would then be able to determine a tumor shrinkage endpoint thanks to a RECIST measurement, which goes to show how complex the system is.
One of the defining features of this experiment is that it makes use of a patient's own bodily cells. This doesn't seem to be much different from stem cell research, which is being conducted right now as well. There are many supporters of this, since they believe that something great will come of it in due time. It's difficult to argue such a thing and I believe that it's easy to make the comparison between one and the other, considering how certain cells are implemented.
It seems easy enough to figure out why this method of glioblastoma research is being done today. While there are, at least, 120 types of tumors known, this particular variant is the most prevalent. It's the one that individuals are stricken with the most, as organizations along the lines of Voices against Brain Cancer will be able to tell you. I can only hope that the work done will be able to appeal to all of those who are afflicted, whether they are patients or not.
It's clear that Northwest has done a great deal of good when it comes to this particular method. It seems like even more will be done in the future, as the article talked a phase III trial that would help the patients along. From what I've seen, solid results will come down the pipeline in 2014, which would be great for those working in this field of research. I believe that, with so many details in existence, it seems like even more of them will be able to help those afflicted in the long run.
An article that was posted on Seeking Alpha talked about a 60-patient phase I/II trial about to be done. Northwest Biotherapeutics would be in charge as the process would be conducted at the MD Anderson Cancer Center. With the immunotherapy DCVax-Direct put into effect, it would grant patients a standard dose. This would then work into the Phase II portion of the experiment, which would then be able to determine a tumor shrinkage endpoint thanks to a RECIST measurement, which goes to show how complex the system is.
One of the defining features of this experiment is that it makes use of a patient's own bodily cells. This doesn't seem to be much different from stem cell research, which is being conducted right now as well. There are many supporters of this, since they believe that something great will come of it in due time. It's difficult to argue such a thing and I believe that it's easy to make the comparison between one and the other, considering how certain cells are implemented.
It seems easy enough to figure out why this method of glioblastoma research is being done today. While there are, at least, 120 types of tumors known, this particular variant is the most prevalent. It's the one that individuals are stricken with the most, as organizations along the lines of Voices against Brain Cancer will be able to tell you. I can only hope that the work done will be able to appeal to all of those who are afflicted, whether they are patients or not.
It's clear that Northwest has done a great deal of good when it comes to this particular method. It seems like even more will be done in the future, as the article talked a phase III trial that would help the patients along. From what I've seen, solid results will come down the pipeline in 2014, which would be great for those working in this field of research. I believe that, with so many details in existence, it seems like even more of them will be able to help those afflicted in the long run.
About the Author:
Contact Voices Against Brain Cancer if you are looking for more information about glioblastoma research.. Free reprint available from: How Immunotherapy May Work Within Glioblastoma Research.
0 comments:
Post a Comment